Atlas Trials

Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma

Clinical trial NCT04788043 · TERMINATED

Trial details

NCT number
NCT04788043
Sponsor
Ranjana Advani
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Hodgkin LymphomaClassic Hodgkin LymphomaRelapsed Classical Hodgkin LymphomaRefractory Classic Hodgkin Lymphoma
Start date
2022-06-21
Primary completion
2024-10-11
Enrollment
8

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.